Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|41|9|867-876

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.41, Iss.9, 2015-05, pp. : 867-876

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 3, 2015-08 ,pp. : 243-257

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 684-693

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 90-96

John Wiley & Sons Inc

Access to resources Recommend Favorite

P061: Interruption of nucleos(t)ide analogue therapy in HBeAg‐negative chronic hepatitis B ‐ a new concept to achieve HBsAg reduction?

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 50-50

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: which patients with hepatitis B virus‐related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 908-910

John Wiley & Sons Inc

Access to resources Recommend Favorite